Project Grant R34HL177446
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This Project Grant award, totaling $499,585.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The University of Texas Health Science Center at Tyler. The project aims to develop a novel therapeutic strategy called "Two-Target Fibrinolytic Therapy" (T2FT) to increase the efficacy of empyema treatment. The research involves preclinical testing and optimization of a combination therapy using alteplase (ALT), a docking site...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) in the amount of $772,400.00 supports research on developing decellularized cartilage and progenitor cells for laryngotracheal reconstruction. The project aims to address the high failure rate and restenosis issues associated with current laryngotracheal reconstruction procedures in children with severe subglottic stenosis, a narrowing of the airway below the vocal...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
- This $502,536 federal Project Grant awarded on January 1, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research training program in pediatric classical hematology at St. Jude Children's Research Hospital Inc. The program will provide enriched training for three postdoctoral fellows to conduct hypothesis-driven research aimed at elucidating the mechanisms of non-malignant blood disorders and identifying new therapeutic...
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $180,174 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia Research Institute. The grant will fund a study to develop a framework for designing the next generation of pediatric acute respiratory distress syndrome (ARDS) clinical trials. Key objectives include: 1) Comparing heterogeneity of treatment effect (HTE) analysis methodologies in a trial of pediatric...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- This Project Grant award for $445,000.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research conducted by The Children's Hospital of Philadelphia (CHOP) to study the role of neutrophil extracellular traps (NETs) in inflammatory and thrombotic diseases. The project aims to characterize the role of NETs in immune homeostasis, determine the mechanisms by which NET stabilization...
- This Project Grant award for $879,567.00, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on lung injury in pediatric hematopoietic cell transplant (HCT) recipients. The research team at The Children's Hospital of Philadelphia (CHOP) will conduct a comprehensive characterization of the clinical, proteomic, and cell-free DNA biomarker profiles associated with the development of lung injury after HCT in...
- The National Heart Lung and Blood Institute awarded a $719,882 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to elucidate lung-specific immune pathways driving post-hematopoietic cell transplant lung injury in children. The research aims to identify cellular and molecular targets for precision diagnostics and therapeutics. Specifically, the project will leverage bronchoalveolar lavage fluid...